Seegene

Seegene CROIC

The Cash Return on Invested Capital (CROIC) of Seegene (096530.KQ) as of Nov 3, 2026 is 10.72 %. In the previous year, Cash Return on Invested Capital (CROIC) was 4.26 % — a change of 151.36% (higher).

CROIC

10.72 %

YoY

151.36%

Last updated:

Cash Return on Invested Capital (CROIC) of Seegene is 2025 10.72 % . Cash Return on Invested Capital (CROIC) of Seegene was 2024 4.26 % . It decreases by 151.36% higher compared to the previous year.

The Seegene CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
8.01 KRW
Jan 1, 2019
13.76 KRW
Jan 1, 2020
27.94 KRW
Jan 1, 2021
21.96 KRW
Jan 1, 2022
19.57 KRW
Jan 1, 2023
6.13 KRW
Jan 1, 2024
4.26 KRW
Jan 1, 2025
10.72 KRW
The Seegene CROIC history
YEARCROICYoY
10.72 %+151.36%
4.26 %-30.40%
6.13 %-68.69%
19.57 %-10.88%
21.96 %-21.43%
27.94 %+103.01%
13.76 %+71.79%
8.01 %+119.65%
3.65 %+19.80%
3.05 %-151.30%
-5.94 %-279.92%
3.30 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Seegene Stock analysis

What does Seegene do? Seegene, Inc. generates revenue through the manufacturing and distribution of molecular diagnostics and reagents. The company offers infectious pathogens inspection products, including those for allergic respiratory pathogens, sexually transmitted diseases, and human papilloma virus (HPV), alongside drug resistance, single nucleotide polymorphisms (SNP), and somatic mutation cancer inspection products. It also provides automatic real-time detection instruments under the brand names Seeplex, Anyplex, and Magicplex. The firm serves both domestic and overseas markets with these products. The primary customers for Seegene's products are healthcare providers and laboratories requiring diagnostic solutions. The company's product portfolio targets specific medical needs such as infectious disease testing and cancer diagnostics. Its brands Seeplex, Anyplex, and Magicplex are used across various diagnostic applications, including respiratory and sexually transmitted disease testing. The firm's focus on molecular diagnostics positions it within the healthcare sector for specialized testing services. Seegene's revenue streams are derived from the sale of its branded diagnostic products and instruments. The company's domestic and overseas market distribution strategy supports its business model, with Seeplex, Anyplex, and Magicplex serving as key product lines. The firm's offerings cater to the growing demand for accurate and efficient molecular diagnostic solutions in healthcare settings. Seegene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Seegene stock

Cash Return on Invested Capital (CROIC) of Seegene is 10.72 % in 2025.

Cash Return on Invested Capital (CROIC) of Seegene changed from 4.26 % to 10.72 %, representing a 151.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Seegene since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Seegene with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Seegene

All Key Metrics — Seegene